PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

Description:

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

There are very low HPV vaccine coverage rates in France and GlobalData expects this to continue throughout the forecast period, especially while the burden of vaccine cost falls partially on the patient. GlobalData anticipates that the low coverage rates for HPV vaccination in Germany will persist throughout the forecast period. Although lower than for other vaccines, coverage rates for HPV vaccination in Italy are higher than for many European countries. Compared with other countries Spain has relatively high coverage rates for HPV vaccination, which GlobalData expects will persist throughout the forecast period. Due to the comprehensive nature of its school-based immunization program, the UK has high HPV vaccine coverage rates.

Scope

- Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the 5EU from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Prophylactic Human Papillomavirus Vaccines disease market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the 5EU

Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Vaccination Recommendations and Coverage Rates
4.1 France
4.1.1 Vaccination Recommendations and Policies
4.1.2 Vaccination Coverage
4.1.3 Clinical Practice
4.2 Germany
4.2.1 Vaccination Recommendations and Policies
4.2.2 Vaccination Coverage
4.2.3 Clinical Practice
4.3 Italy
4.3.1 Vaccination Recommendations and Policies
4.3.2 Vaccination Coverage
4.3.3 Clinical Practice
4.4 Spain
4.4.1 Vaccination Recommendations and Policies
4.4.2 Vaccination Coverage
4.4.3 Clinical Practice
4.5 UK
4.5.1 Vaccination Recommendations and Policies
4.5.2 Vaccination Coverage
4.5.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles
5.3.1 Gardasil
5.3.2 Cervarix
6 Unmet Need and Opportunity
6.1 Overview
6.2 Protection against Multiple HPV Types
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Vaccine Coverage Rates
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Perception of Vaccine Safety
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Awareness of HPV Vaccination
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Affordability of HPV Vaccines
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Coverage of HPV Types Prevalent in Certain Populations
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
6.8 Vaccine Compliance Rates
6.8.1 Unmet Need
6.8.2 Gap Analysis
6.8.3 Opportunity
6.9 Lifelong Protection from HPV Infection Not Established
6.9.1 Unmet Need
6.9.2 Gap Analysis
Table 9: Gardasil SWOT Analysis, 2014
Table 10: Product Profile - Cervarix
Table 11: Phase III Efficacy Trials - Cervarix
Table 12: Safety Profile - Cervarix
Table 13: Cervarix SWOT Analysis, 2014
Table 14: Overall Unmet Needs - Current and Future Level of Attainment
Table 15: HPV Vaccines - Phase Pipeline, 2014
Table 16: Product Profile - V503
Table 17: V503 SWOT Analysis, 2013
Table 18: Bivalent Vaccine (Xiamen Innovax) SWOT Analysis, 2014
Table 19: Sales Forecasts ($m) for HPV Vaccines in France, 2012-2022
Table 20: Key Events Impacting Sales for HPV Vaccines in France, 2012-2022
Table 21: France HPV Vaccine Market - Drivers and Barriers, 2014
Table 22: Sales Forecasts ($m) for HPV Vaccines in Germany, 2012-2022
Table 23: Key Events Impacting Sales for HPV Vaccines in Germany, 2014
Table 24: Germany HPV Vaccine Market - Drivers and Barriers, 2014
Table 25: Sales Forecasts ($m) for HPV Vaccines in Italy, 2012-2022
Table 26: Key Events Impacting Sales for HPV Vaccines in Italy, 2014
Table 27: Italy HPV Vaccine Market - Drivers and Barriers, 2014
Table 28: Sales Forecasts ($m) for HPV Vaccines in Spain, 2012-2022
Table 29: Key Events Impacting Sales for HPV Vaccines in Spain, 2012-2022
Table 30: Spain HPV Vaccine Market - Drivers and Barriers, 2014
Table 31: Sales Forecasts ($) for HPV Vaccines in the United Kingdom, 2012-2022
Table 32: Key Events Impacting Sales for HPV Vaccines in the United Kingdom, 2012-2022
Table 33: United Kingdom HPV Vaccine Market - Drivers and Barriers, 2014
Table 34: Key Launch Dates
Table 35: Key Patent Expiries
Table 36: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Historical and Projected HPV Vaccination Coverage (%) in France among 14-Year-Old Females, 2007-2022
Figure 2: Historical and Projected HPV Vaccination Coverage (%) in Germany among 17-Year-Old Females, 2009-2022
Figure 3: Historical and Projected HPV Vaccination Coverage (%) in Italy among 12-Year-Old Females, 2009-2022
Figure 4: Historical and Projected HPV Vaccination Coverage (%) in Spain among 14-Year-Old Females, 2008-2022
Figure 5: Historical and Projected HPV Vaccination Coverage (%) in the United Kingdom among 12-Year-Old Females, 2008-2022
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022
Figure 7: Sales for HPV Vaccines in France by Vaccine Class, 2012-2022
Figure 8: Sales for HPV Vaccines in Germany by Vaccine Class, 2012-2022
Figure 9: Sales for HPV Vaccines in Italy by Vaccine Class, 2012-2022
Figure 10: Sales for HPV Vaccines in Spain by Vaccine Class, 2012-2022
Figure 11: Sales for HPV Vaccines in the United Kingdom by Vaccine Class, 2012-2022

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name:          | PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 |
| Web Address:          | http://www.researchandmarkets.com/reports/2881938/ |
| Office Code:          | SC6I5RXD |

Product Formats
Please select the product formats and quantity you require:

- Electronic (PDF) - Single User: $6995
- Electronic (PDF) - Site License: $13990
- Electronic (PDF) - Enterprisewide: $20985

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World